IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Buys 23,526 Shares of Company Stock

Posted by Francis Steltz on Oct 8th, 2026

IRIDEX Corporation (NASDAQ:IRIX – Get Free Report) major shareholder Shih-Yao David Lin acquired 23,526 shares of the company’s stock in a transaction on Wednesday, May 28th. The stock was bought at an average cost of $0.94 per share, with a total value of $22,114.44. Following the completion of the acquisition, the insider directly owned 476,351 shares in the company, valued at approximately $447,769.94. This represents a 5.20% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

IRIDEX Stock Performance

IRIX opened at $0.88 on Thursday. IRIDEX Corporation has a 52-week low of $0.61 and a 52-week high of $1.65. The firm has a market cap of $15.46 million, a P/E ratio of -4.40 and a beta of 0.67. The business’s fifty day moving average is $0.73 and its 200-day moving average is $0.95.

IRIDEX (NASDAQ:IRIX – Get Free Report) last posted its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The company had revenue of $12.57 million during the quarter, compared to analyst estimates of $13.59 million. On average, research analysts predict that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

More IRIDEX News

Here are the key news stories impacting IRIDEX this week:

Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $3.00.

Check Out Our Latest Research Report on IRIX

Hedge Funds Weigh In On IRIDEX

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new position in shares of IRIDEX during the 2nd quarter worth $29,000. Diversify Advisory Services LLC acquired a new stake in IRIDEX in the second quarter valued at about $30,000. Diversify Wealth Management LLC acquired a new stake in IRIDEX in the first quarter valued at about $35,000. United Capital Financial Advisors LLC bought a new position in IRIDEX in the second quarter valued at about $41,000. Finally, Thompson Davis & CO. Inc. grew its position in IRIDEX by 66.5% in the first quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock valued at $48,000 after acquiring an additional 18,944 shares during the last quarter. Institutional investors own 20.10% of the company’s stock.

IRIDEX Company Profile

(Get Free Report)

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.